Testing a new cell therapy for newly diagnosed type 1 diabetes

This study is testing a new treatment called GNTI-122 for adults who were recently diagnosed with type 1 diabetes. GNTI-122 is a cell therapy made from your own blood cells, designed to help restore balance to your immune system and potentially preserve your body's ability to make insulin. The trial will check whether the medication is safe, how well it's tolerated, and whether it helps your body produce more of its own insulin over time.

Type 1 diabetes happens when the immune system mistakenly attacks the cells that produce insulin. This medication aims to correct that immune imbalance by using specially processed cells from your own blood. Researchers hope this new treatment could slow or stop the loss of insulin-producing cells, especially if given soon after diagnosis.